CN1260835A - 截短的vegf相关蛋白质 - Google Patents

截短的vegf相关蛋白质 Download PDF

Info

Publication number
CN1260835A
CN1260835A CN98806232A CN98806232A CN1260835A CN 1260835 A CN1260835 A CN 1260835A CN 98806232 A CN98806232 A CN 98806232A CN 98806232 A CN98806232 A CN 98806232A CN 1260835 A CN1260835 A CN 1260835A
Authority
CN
China
Prior art keywords
vrp
truncated
subunit
pro
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98806232A
Other languages
English (en)
Chinese (zh)
Inventor
皮特·波赫恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Collateral Therapeutics Inc
Original Assignee
Collateral Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Collateral Therapeutics Inc filed Critical Collateral Therapeutics Inc
Publication of CN1260835A publication Critical patent/CN1260835A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN98806232A 1997-04-25 1998-04-20 截短的vegf相关蛋白质 Pending CN1260835A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84298497A 1997-04-25 1997-04-25
US08/842,984 1997-04-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA200510009104XA Division CN1680442A (zh) 1997-04-25 1998-04-20 截短的vegf相关蛋白质

Publications (1)

Publication Number Publication Date
CN1260835A true CN1260835A (zh) 2000-07-19

Family

ID=25288752

Family Applications (2)

Application Number Title Priority Date Filing Date
CN98806232A Pending CN1260835A (zh) 1997-04-25 1998-04-20 截短的vegf相关蛋白质
CNA200510009104XA Pending CN1680442A (zh) 1997-04-25 1998-04-20 截短的vegf相关蛋白质

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA200510009104XA Pending CN1680442A (zh) 1997-04-25 1998-04-20 截短的vegf相关蛋白质

Country Status (10)

Country Link
EP (1) EP0977854A2 (https=)
JP (1) JP2001524828A (https=)
KR (1) KR20010020259A (https=)
CN (2) CN1260835A (https=)
AU (1) AU7250298A (https=)
CA (1) CA2287538A1 (https=)
EA (1) EA199900861A1 (https=)
IL (1) IL132537A0 (https=)
NZ (2) NZ500530A (https=)
WO (1) WO1998049300A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118546231A (zh) * 2024-06-28 2024-08-27 温州医科大学 一种修复皮肤屏障的vegf改构蛋白及其在植物中表达的方法

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
ES2249762T3 (es) 1994-03-08 2006-04-01 Human Genome Sciences, Inc. Factor de crecimiento del endotelio vascular 2.
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
DE69628652T3 (de) 1995-09-08 2012-05-03 Genentech, Inc. Vegf-verwandtes protein
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
CA2322748A1 (en) * 1998-03-13 1999-09-16 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
EP1121143A2 (en) * 1998-03-27 2001-08-08 Dorothea J. Eicher Vegf and vegf-c as infant formula supplements
DE19813774A1 (de) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)
US6316603B1 (en) 1998-09-08 2001-11-13 Agouron Pharmaceuticals, Inc. Modifications of the VEGF receptor-2 protein and methods of use
EP1126870B1 (en) * 1998-10-26 2004-09-08 Ludwig Institute For Cancer Research Use of vegf-c or vegf-d gene or protein to prevent restenosis
EP1568375A1 (en) * 1998-10-26 2005-08-31 Ludwig Institute For Cancer Research Use of VEGF-C or VEGF-D gene or protein to prevent restenosis
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
CA2348835A1 (en) 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US7727971B2 (en) 2000-02-04 2010-06-01 Life Sciences Research Partners Vzw Use of placental growth factor for treating ischemic muscle disease
AU4643501A (en) * 2000-02-04 2001-08-14 Flanders Interuniversity Institute For Biotechnology (Vib) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
AU5523701A (en) 2000-04-06 2001-10-23 Wayne P Franco Methods of using growth factors for treating heart disease
EP1157999A1 (en) * 2000-05-24 2001-11-28 Introgene B.V. Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
MXPA02003434A (es) 2000-08-04 2002-09-02 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
WO2002014367A1 (fr) * 2000-08-10 2002-02-21 Center For Advanced Science And Technology Incubation,Ltd. Facteur de croissance chimere de cellules endotheliales vasculaires de type humain
EP1191104A1 (en) * 2000-09-26 2002-03-27 Introgene B.V. Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
AU2002228841C1 (en) 2000-12-07 2006-11-23 Sangamo Biosciences, Inc Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
NZ529915A (en) 2001-06-20 2007-07-27 Ludwig Inst Cancer Res Stimulation of vascularization of ischemic tissue by angiogenesis with VEGF-B186
NZ531733A (en) 2001-10-15 2006-04-28 Janssen Pharmaceutica Nv Substituted 4-phenyl-4-[1H-imidazol-2-YL]- piperidine derivatives for reducing ischaemic damage
KR101021387B1 (ko) 2002-04-25 2011-03-14 크루셀 홀란드 비.브이. 아데노바이러스 벡터를 생산하기 위한 수단 및 방법
EP1827494A4 (en) * 2004-11-18 2010-02-17 Wayne Franco COMBINATION GROWTH THERAPY AND CELL THERAPY FOR THE TREATMENT OF ACUTE AND CHRONIC ORGANIC DISEASES
WO2010078624A1 (en) * 2009-01-07 2010-07-15 Vegenics Limited Materials and methods for the treatment of hypertension

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1242149B (it) * 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
JPH08506008A (ja) * 1992-11-18 1996-07-02 アーチ ディベロプメント コーポレイション 心筋及び血管平滑筋へのアデノウィルス介在遺伝子移入
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
WO1996026742A1 (en) * 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
NZ301611A (en) * 1995-03-02 2000-02-28 Amrad Operations Pty Ltd a peptide having vascular endothelial growth factor like properties, nucleic acid molecule encoding it and its use
WO1996039421A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human vascular endothelial growth factor 3

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118546231A (zh) * 2024-06-28 2024-08-27 温州医科大学 一种修复皮肤屏障的vegf改构蛋白及其在植物中表达的方法

Also Published As

Publication number Publication date
EP0977854A2 (en) 2000-02-09
AU7250298A (en) 1998-11-24
WO1998049300A2 (en) 1998-11-05
IL132537A0 (en) 2001-03-19
EA199900861A1 (ru) 2000-06-26
NZ500530A (en) 2001-12-21
NZ514872A (en) 2005-01-28
KR20010020259A (ko) 2001-03-15
CA2287538A1 (en) 1998-11-05
WO1998049300A3 (en) 1999-03-11
JP2001524828A (ja) 2001-12-04
CN1680442A (zh) 2005-10-12

Similar Documents

Publication Publication Date Title
CN1260835A (zh) 截短的vegf相关蛋白质
CN1146440C (zh) 血管内皮生长因子-b
EP0925360B1 (en) Use of angiogenic factor vegf145 in treating cardiovascular disease
US6479654B1 (en) Forms of the angiogenic factor vascular endothelial cell growth factor: VEGF
CN1211126C (zh) 血管内皮生长因子2
CN1552855A (zh) 人血管内皮生长因子2
CN1299407A (zh) 血管内皮生长因子2
CN1330664A (zh) 血小板衍生生长因子c、其编码dna及其应用
US20030165467A1 (en) Angiogenic factor and use thereof in treating cardiovascular disease
CN1240836C (zh) 转化生长因子αHI
CN1414020A (zh) 成纤维细胞生长因子11的抗体、拮抗剂及激动剂
EP1426444A2 (en) Use of the angiogenic factor VEGF145 in treating cardiovascular diseases
US20060084622A1 (en) Angiogenic factor and use thereof in treating cardiovascular disease
HK1008485B (en) Vascular endothelial growth factor-b
CN1414101A (zh) 成纤维细胞生长因子11
CN1242043A (zh) 受体配体vegf-c
HK1056999A (en) Vascular endothelial growth factor 2
HK1020756B (en) Use of angiogenic factor vegf145 in treating cardiovascular disease
HK1037679A (en) Vascular endothelial growth factor 2
AU8936101A (en) Angiogenic factor and use thereof in treating cardiovascular disease
AU2004200697A1 (en) Variants of the Angiogenic Factor Vascular Endothelial Cell Growth Factor: VEGF

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication